Boston Sci snags $71M DOD contract

Boston Scientific

The Department of Defense awarded Boston Scientific a contract worth up to $71 million to supply it with cardiovascular devices.

The one-year deal could potentially be extended another four years, according to the DOD. Under the contract, the Massachusetts devicemaker will supply cardiovascular products to the Army, Navy, Air Force, Marine Corps and federal civilian agencies.

Boston Scientific’s cardiovascular business is the company’s largest. It logged a couple of key FDA nods in 2015, namely the February approval of its stroke-fighting Watchman after setbacks in 2010 and 2014 and the October OK for its Synergy stent, the first partially bioresorbable stent.

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

As for 2016, the company nabbed a CE mark for its next-gen TAVR, the Lotus Edge Valve System. Also in 2016, Boston Scientific rolled out a cloud-based digital care platform in partnership with Accenture, which aims to provide hospitals with more insight into their chronic cardiovascular patients. The Advantics Care Pathway Transformation is focused on evaluating the care delivery for heart failure patients and how it can be improved.

Outside of cardiovascular, Boston Scientific inked a deal to acquire EndoChoice for approximately $210 million, boosting its endoscopy offerings. And in July, the company picked up Cosman Medical for an undisclosed amount to gain ground in neuromodulation. Endoscopy and Neuromodulation, along with Urology/Pelvic Health, make up the company’s Medsurg unit, its second largest business.

Suggested Articles

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.

Emmecell aims to make corneal transplant surgery, which can take up to a year to heal from and fails up to 20% of the time, a relic of the past.

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.